Company overview
Akoya Biosciences, now part of Quanterix, provides end-to-end spatial biology platforms including PhenoCycler (formerly CODEX) for high-parameter tissue analysis with over 40 markers and Phenoptics for translational and clinical research. These solutions support biomarker discovery, immuno-oncology drug development, and precise therapies from discovery to clinical trials. The platforms enable spatial phenotyping to understand complex diseases like cancer.
Ultra-Sensitive Biomarker Detection is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include spatial biology, tissue analysis, phenocycler, phenoptics, immuno-oncology.
Structured facts
- Website
- https://www.akoyabio.com
- Markets served
- United States & Americas
- Keywords
- spatial biology, tissue analysis, phenocycler, phenoptics, immuno-oncology
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What spatial biology platforms does Akoya offer?
- Akoya offers PhenoCycler (formerly CODEX) for assessing over 40 markers in biomarker discovery and Phenoptics for assay robustness in translational and clinical research.
- What applications are Akoya's solutions used for?
- The platforms support high-parameter tissue analysis for immuno-oncology, drug development, and understanding complex diseases like cancer from discovery through clinical trials.
- Who acquired Akoya Biosciences and when?
- Quanterix completed the acquisition of Akoya Biosciences on July 8, 2025, creating an integrated platform for blood and tissue biomarker detection.
Related editorial coverage
- Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk
- ACRP 2026: Immunology Clinical Research Trends to Watch
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
